Overview

View the Digital Invitation (PDF). Agenda Items Include:

• Highlight Exact Sciences portfolio of genomic and genetic tests that can help inform personalized treatment decisions
• Introduce the Riskguard™ & Oncotype DX Breast Recurrence Score® tests
• Discuss the utility of testing with both the Oncotype DX® and Riskguard™ tests

Faculty:

• Jennifer M Racz, MD, MBA, FRCSC
  Director, Medical Affairs, Oncology
  Exact Sciences
• Brandie Heald Leach, MS, CGC
  Senior Director, Medical Affairs, Hereditary Cancer
  Exact Sciences

Overview

As genetic counseling is recommended for an increasing number of patients with cancer, institutions are looking for new strategies to meet this growing demand. By developing efficient genetic counseling and testing service delivery models, more patients may be able to access crucial testing and targeted cancer treatment.

Hear directly from a genetic counselor at a community health system and a genetic counselor at an academic medical center as they share examples of alternative service delivery models, challenges they faced during the implementation of these workflows, and their impact on expanding access to genetic testing for appropriate patients.

Key Topics Include:

• Strategies for accessible education in the pretest setting
• Frameworks to integrate patients, physicians, nurse navigators, and testing coordinators into the genetic counseling process
• Workflows to get genetic testing results quickly and streamline quality care

You can find this important roundtable discussion HERE.

Overview

As technology advances, surgeons need to develop tools to assess the value of new devices and initiatives in patient care. Surgeons will also need to understand the processes by which their institutions evaluate new technology for integration into the system.

Presented by:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine
  Director of Breast Surgery
  NYU Langone Health
  New York, NY

Overview

In this informative webinar, participants will learn more about:

• Early Detection & Intervention for Subclinical Lymphedema:
  Why It's Important for Our Patients
• Clinical Practice Guidelines & PREVENT Trial Analysis Updates:
  Evidence-Based Insights Supporting Early Detection of Lymphedema
• Operationalizing a Lymphedema Surveillance Program:
  Best Practices for Implementation & Patient Compliance

Overview

Join Breast Surgical Oncologists Dr. Rachel Kaczynski and Dr. Amani Jambhekar, as they share their journey of establishing and building their practices in two different locations, each facing different challenges. Discover how they justified and acquired the KUBTEC MOZART 3D Specimen Radiography System, how it has impacted their practice, and how they present their use of advanced technology to the wider world.

Presenters:

• Rachel E. Kaczynski, DO, FACOS
  Surgical Oncologist, Texas Breast Specialists,
  San Antonio, Texas
• Amani Jambhekar MD, MBA
  Medical Director of Surgical Breast Oncology, CHRISTUS St. Vincent Regional Cancer Center,
  Santa Fe, NM

Overview

This session will educate the audience on how to incorporate genetic and genomic testing insights into clinical practice in order to guide personalized and preventative care and optimize surgical decision making for patients.

Presenters:

• David Weintritt, MD, FACS
  Breast Cancer Surgeon at Virginia Cancer Specialists
• Laura Brzeskiewicz, MS, CGC
  Manager, Medical Science Liaisons at Myriad Genetics

Overview

In Part 2 of our 3-Part series exploring the comprehensive genetics and genomics landscape in breast cancer, we'll dive into Risk Assessment and High-Risk Management. Come along as we explore strategies and tests to assess breast cancer risk and tools for implementing a high-risk breast program in your practice. Let's identify patients together who are at high risk for breast cancer so we can #BeatBreastCancer.

Overview

Join Eric Manahan, MD, MBA, FACS, a leading expert in general and breast surgery, as he shares insights on trending topics in genetic testing for breast cancer. In this webinar, Dr. Manahan covers the importance and underutilization of genetic testing in breast cancer, disparities in genetic testing, unlocking the potential of tumor genomics, exciting research opportunities, and much more. Don't miss out — register today to secure your spot and gain valuable insights on how to elevate your approach to patient care.

Overview

Join us as we take a dive deep into how tumor-informed molecular residual disease (MRD) testing is being integrated into clinical practice today as a valuable tool to help guide treatment decisions for patients with breast cancer. Our expert panel will review the various applications of tumor-informed ctDNA assessment in the neoadjuvant, adjuvant and surveillance settings.

Presenters:

• Angel Rodriguez, MD
  Medical Oncologist, Breast Medical Director
  Natera
• Erica Giblin, MD
  Surgeon, Breast Cancer Specialistr
  Ascension St. Vincent

Overview

As an elite surgeon, you work so hard to do what’s best for your patients and achieve better outcomes, but you can’t see what you need to see in the operating room. Standard technologies lack the resolution to visualize microscopic features associated with early-stage disease in the margins.

Perimeter’s Optical Coherence Tomography (OCT), a category first technology, delivers ultra-high-resolution margin visualization, giving surgeons the ability to gain real-time clarity on margin status. The S-Series OCT offers 10x the resolution of X-ray and ultrasound at 2mm imaging depth, making it a suitable tool for imaging difficult-to-detect disease at the cellular level.

In this webinar, breast surgeons will discuss how OCT helps them control their outcomes and close with confidence.

Why Attend?

• Learn about how OCT provides surgeons with clarity and confidence in the OR
• Hear breast surgeons review cases with OCT technology
• Ask your questions during a live Q&A

Speakers:

• Amani Jambhekar, MD, MBA, FACS
  CHRISTUS St. Vincent
• Jennifer Titensor, MD,
  Utah Surgical Associates
• Catherine A. Ronaghan, MD, FACS
  St. Joseph’s/Candler

Overview

Discover the latest insights from a peer-reviewed study conducted by physicians at MD Anderson and UT Health Houston. This webinar will delve into the critical issue of reoperations in BCS, exploring the associated costs, complications, and profound impact on patients and healthcare systems. This webinar presents a unique opportunity to hear from Dr. Nina Tamirisa, contributing author in the MD Anderson and UT Health study, and Dr. Ted James, as they highlight:

• Trends in Reoperation Rates: Understand the current statistics and trends in reoperation rates following BCS.
• Implications for Patients and Healthcare Systems: Learn about the physical, emotional, and financial burdens reoperations place on patients and the broader healthcare system.
• Strategies to Reduce Reoperations: Gain insights into practices aimed at reducing reoperation rates.
• Live Q&A: Ask your questions to leading experts in the field.

Faculty:

• Nina Tamirisa, MD
  Breast Surgical Oncologist,
  MD Anderson Cancer Center
• Ted James, MD, MHCM, FACS
  Chief of Breast Surgical Oncology,
  Beth Israel Deaconess Medical Center

Overview

• Evaluate latest evidence regarding breast cancer gene mutations in the DNA damage repair (DDR) pathway (eg, BRCA, PALB2, ATM) and their implications on therapeutic and surgical decision-making
• Analyze recent breast cancer genetic testing guideline recommendations and the role of various members of the multidisciplinary team, including surgeons, advanced practice providers, genetic counselors, patient navigators, pharmacists, and nurses in optimizing genetic testing processes for eligible patients in the newly diagnosed breast cancer setting
• Individualize breast cancer treatment selection for DDR-mutated, early-stage and metastatic breast cancers based on the latest safety and efficacy trial data, guideline recommendations, and genetic testing results
• Employ multidisciplinary care coordination models as a means to effectively integrate genetic testing into clinical practice, including considerations for pre- and post-test counseling and informed consent, to optimize breast cancer management and overall outcomes

Overview

This lecture will focus on all types of breast localization, from wire to wire-free options and how each have the potential to increase patient comfort and surgery scheduling flexibility.

Speaker:

• Steven Cai, MD, FACS

CME Information

World Class CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians and designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. This activity is supported by an unrestricted educational grant from Hologic, Inc.

Overview

During this program, a multidisciplinary panel of experts will discuss the role and importance of surgeons in genetic testing in early breast cancer. Topics will include key characteristics and unmet needs of patients with germline BRCA mutations (gBRCAm), collaborating with the multidisciplinary team to integrate genetic testing in practice, genetic counseling considerations and how gBRCAm testing may inform clinical decisions. View prescribing information.

Program Objectives:

• Discuss the need for individualized care plans for patients with gBRCAm breast cancer due to differences in underlying tumor biology vs non-gBRCAm patients
• Discuss the surgical and treatment implications for patients with gBRCAm eBC
• Explore the role and importance of surgeons within the BRCA testing pathway

Description:

Positive lumpectomy margins are associated with an increased risk for ipsilateral tumor recurrence and necessitate additional procedures to achieve acceptable margins. Re-excision rates are higher in patients with ductal carcinoma in situ (DCIS) versus those with invasive carcinoma. The purpose of this program is to lead a discussion on the clinicopathologic characteristics, surgical techniques, and other outcomes associated with re-excision over time following primary breast conserving surgery.

Faculty:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine, Director of Breast Surgery NYU Langone

For More Information:

Contact Nancy King at nking@dilon.com.

Program Objectives:

• Review the wealth of data on the Oncotype DX Breast Recurrence Score® test in pre- and postmenopausal patients
• Interrogate current controversies at the intersection of genomic testing with patient menopausal status, local regional recurrence, and clinicopathologic features
• Discuss how guidelines have been informed by TAILORx and RxPONDER trials

Speakers:

• Tari King, MD, Chief, Breast Surgery, Dana Farber/Brigham and Women's Hospital
• Christy Russell, MD, Vice President, Medical Affairs, Exact Sciences
• Jennifer Racz, MD, Director, Medical Affairs, Oncology, Exact Sciences

For More Information:

Go to www.OncotypeIQ.com.

Overview:

See how surgeons around the world are using a single platform to achieve optimal clinical results while tailoring treatments for their patients. Enjoy hands-on experience with devices from biopsy to surgery and see what new technologies are on the horizon.

Faculty:

• Michael Alvarado, MD, University of California San Francisco
• Kandace P. McGuire, MD, Virginia Commonwealth University
• Eirini Pantiora, MD, Uppsala University Hospital, Sweden
• Rhiana Menen, MD, St. Luke's, Idaho

Agenda:

• Evidence-Based Decisions: What Will You Decide?
• Changing the Standard: The Evolution of Magtrace®
• Clinical Roundup: Thinking Global
• Ready, Set, Action! The Future of Magnetic Localization

For More Information:

Go to www.mammotome.com.

Overview

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to targeted axillary dissection to excellent surgical outcomes. Discover the state-of-the art localization techniques practiced by key opinion leaders from around the country. Learn how recent product innovations enable placing SCOUT under MRI guidance, future platform enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy, providing a better patient experience, and streamlining workflow.

Overview

Welcome to the first installment of a 3-part series centered around the entire genetics and genomics landscape in breast cancer, covering patients at high risk, those who are newly diagnosed, undergoing treatment, or in survivorship. This series will equip you with the expertise to seamlessly integrate genetic and genomic testing into your clinical practice.

In part 1, we will delve into the foundations and applications of germline testing. Join us as we engage with experts in the field, including Jennifer Lazzara, DNP, ARNP, CGRA, who leads a Breast Cancer Genetics Clinic at Cancer Care Northwest, and Laura Brzeskiewicz, CGC, and Medical Science Liaison Manager at Myriad Genetics.

Overview:

Watch this informative webinar where subject matter experts in breast cancer review the various clinical applications of MRD testing using ctDNA testing to monitor high-risk patients. Learn more about the latest Signatera™ data in high-risk breast cancer:

Speakers:

• Dr. Minetta Liu, Chief Medical Officer, Natera Oncology
• Dr. Barry Rosen, Breast Surgical Oncologist, Advocate Good Shepard Hospital
• Dr. Angel Rodriguez, Breast Medical Oncologist, Medical Director, Natera Oncology

For More Information:

Please contact abet@natera.com.

Overview

View the replay of this educational session at the American Society of Breast Surgeons' 2023 Annual Meeting on how Perimeter’s margin visualization technology gives surgeons the real-time insights they need to personalize clinical decisions at the point of care.

Overview

Overview

Pathogenic germline BRCA mutations profoundly influence breast cancer risk, with carriers facing lifetime penetrance exceeding 60% and heightened vulnerability to subsequent malignancies. Genetic testing is crucial for informing prophylactic measures, surgical decisions, and therapeutic strategies, yet remains severely underutilized. This expert-led, evidence-based webcast series provides surgeons and advanced practice providers with essential skills to identify testing candidates, provide comprehensive patient counseling, and offer personalized therapy – ultimately improving outcomes for patients with hereditary breast cancer predisposition. Join Drs. Mamounas and Robson for the first webcast to hear their insights on integrating updated testing guidelines into practice.

Target Audience

This educational activity is designed to meet the needs of breast and general surgeons and surgical advanced practice professionals who treat and manage patients with breast cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

1. Apply germline mutation testing based on recently updated guidelines to identify patients at high risk of developing breast cancer and personalize preventive and treatment decisions
2. Integrate alternative models in the delivery of germline testing with focus on integrating surgeons and oncology advanced practitioners in the delivery of germline testing and pre- and post- patient counseling

Faculty Presenters

• Eleftherios Mamounas, MD, MPH, FACS
  Medical Director, Breast Program and Research Activities
  AdventHealth Cancer Institute
  Professor of Surgery
  University of Central Florida
  Clinical Professor of Clinical Sciences
  Florida State University College of Medicine
  Tallahassee, Florida
• Mark Robson, MD
  Chief, Breast Medicine Service
  Attending Physician
  Breast Medicine and Clinical Genetics Services
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York

Faculty Disclosures

• Eleftherios Mamounas, MD, MPH, FACS
  Consultant: Biotheranostics, Delphi Diagnostics, Exact Sciences, GE Healthcare, Merck, Novartis, Provapharm
  Speaker: Exact Sciences, Merck, Novartis
  Stock Ownership: Moderna
• Mark Robson, MD
  Advisory Boards: Artios Pharma, AstraZeneca, Change Healthcare, Daiichi Sankyo, Epic Sciences, GlaxoSmithKline, Merck, Pfizer, Tempus Lab, Zenith Pharma
  Consultant: Artios Pharma, AstraZeneca, Change Healthcare, Daiichi Sankyo, Epic Sciences, GlaxoSmithKline, Merck, Pfizer, Tempus Lab, Zenith Pharma
  Research Funding: AstraZeneca, Merck, Pfizer

Overview

Pathogenic germline BRCA mutations profoundly influence breast cancer risk, with carriers facing lifetime penetrance exceeding 60% and heightened vulnerability to subsequent malignancies. Genetic testing is crucial for informing prophylactic measures, surgical decisions, and therapeutic strategies, yet remains severely underutilized. This expert-led, evidence-based webcast series provides surgeons and advanced practice providers with essential skills to identify testing candidates, provide comprehensive patient counseling, and offer personalized therapy – ultimately improving outcomes for patients with hereditary breast cancer predisposition. Hear insights from Dr. Kelly Hunt and Dr. Mark Robson on optimizing surgical and therapeutic care.

Target Audience

This educational activity is designed to meet the needs of breast and general surgeons and surgical advanced practice professionals who treat and manage patients with breast cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

1. Apply germline mutation testing based on recently updated guidelines to identify patients at high risk of developing breast cancer and personalize preventive and treatment decisions
2. Integrate alternative models in the delivery of germline testing with focus on integrating surgeons and oncology advanced practitioners in the delivery of germline testing and pre- and post- patient counseling

Faculty Presenters

• Kelly K. Hunt, MD, FACS, FSSO
  Olla Stribling Distinguished Chair for Cancer Research
  Chair, Department of Breast Surgical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
• Mark Robson, MD
  Chief, Breast Medicine Service
  Attending Physician
  Breast Medicine and Clinical Genetics Services
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York

Faculty Disclosures

• Kelly K. Hunt, MD, FACS, FSSO
  Advisory Board: ArmadaHealth
  Editor-in-Chief Current Breast Cancer Reports: Springer Nature
  Honorarium: AstraZeneca
  Research Funding: Cairn Surgical, Lumicell
• Mark Robson, MD
  Advisory Boards: Artios Pharma, AstraZeneca, Change Healthcare, Daiichi Sankyo, Epic Sciences, GlaxoSmithKline, Merck, Pfizer, Tempus Lab, Zenith Pharma
  Consultant: Artios Pharma, AstraZeneca, Change Healthcare, Daiichi Sankyo, Epic Sciences, GlaxoSmithKline, Merck, Pfizer, Tempus Lab, Zenith Pharma
  Research Funding: AstraZeneca, Merck, Pfizer

Overview

Pathogenic germline BRCA mutations profoundly influence breast cancer risk, with carriers facing lifetime penetrance exceeding 60% and heightened vulnerability to subsequent malignancies. Genetic testing is crucial for informing prophylactic measures, surgical decisions, and therapeutic strategies, yet remains severely underutilized. This expert-led, evidence-based webcast series provides surgeons and advanced practice providers with essential skills to identify testing candidates, provide comprehensive patient counseling, and offer personalized therapy – ultimately improving outcomes for patients with hereditary breast cancer predisposition. Hear insights from Dr. Kelly Hunt and Dr. Terry Mamounas on emerging strategies and clinical trials.

Target Audience

This educational activity is designed to meet the needs of breast and general surgeons and surgical advanced practice professionals who treat and manage patients with breast cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

1. Apply germline mutation testing based on recently updated guidelines to identify patients at high risk of developing breast cancer and personalize preventive and treatment decisions
2. Integrate alternative models in the delivery of germline testing with focus on integrating surgeons and oncology advanced practitioners in the delivery of germline testing and pre- and post- patient counseling

Faculty Presenters

• Kelly K. Hunt, MD, FACS, FSSO
  Olla Stribling Distinguished Chair for Cancer Research
  Chair, Department of Breast Surgical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
• Eleftherios Mamounas, MD, MPH, FACS
  Medical Director, Breast Program and Research Activities
  AdventHealth Cancer Institute
  Professor of Surgery
  University of Central Florida
  Clinical Professor of Clinical Sciences
  Florida State University College of Medicine
  Tallahassee, Florida

Faculty Disclosures

• Kelly K. Hunt, MD, FACS, FSSO
  Advisory Board: ArmadaHealth
  Editor-in-Chief Current Breast Cancer Reports: Springer Nature
  Honorarium: AstraZeneca
  Research Funding: Cairn Surgical, Lumicell
• Eleftherios Mamounas, MD, MPH, FACS
  Consultant: Biotheranostics, Delphi Diagnostics, Exact Sciences, GE Healthcare, Merck, Novartis, Provapharm
  Speaker: Exact Sciences, Merck, Novartis
  Stock Ownership: Moderna

Overview

Dr Neil Love, president of Research To Practice (RTP), recently hosted a CME/MOC-accredited webinar, developed in collaboration with the American Society of Breast Surgeons, that focused on localized breast cancer and featured insights from medical oncologists and breast surgeons. As part of this initiative, RTP conducted a case-based survey of breast surgeons to assess clinical decision-making related to genetic testing and management strategies. The results of this survey served as the foundation for Dr Love’s conversation with Drs Kevin S Hughes and Mark Robson, who shared real-world cases, evidence-based recommendations and key research findings.

Topics Discussed

• Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes
• Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson

Moderator

• Neil Love, MD
  Research To Practice
  Miami, Florida

Faculty

• Kevin S Hughes, MD
  Director of Cancer Genetics
  McKoy Rose Professor of Surgery
  Medical University of South Carolina
  Charleston, South Carolina
• Mark E Robson, MD
  Associate Attending Physician
  Clinical Genetics and Breast Medicine Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York

CME/MOC Information

Target Audience

This activity is intended for breast surgeons, medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, and other allied healthcare professionals involved in the treatment of breast cancer.

Accreditation Statement

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) and American Board of Surgery (ABS) — Continuous Certification (CC)

Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.25 (video) and 1.75 (audio) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program and 1.25 (video) and 1.75 (audio) MOC points in the American Board of Surgery’s (ABS) Continuous Certification program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note, these programs have been specifically designed for the following specialties: medical oncology (ABIM) and complex general surgical oncology (ABS).